Ardelyx (ARDX) Cash & Equivalents (2013 - 2026)
Ardelyx's (ARDX) quarterly Cash & Equivalents came in at $31.2 million in Q1 2026, up 1.3% YoY from $30.8 million in Q1 2025, and down 54.1% on a QoQ basis from $68.0 million in Q4 2025.
Ardelyx (ARDX) Cash & Equivalents (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Cash & Equivalents data on file, last reported at $31.2 million in Q1 2026.
- Quarterly Cash & Equivalents rose 1.3% year-over-year to $31.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.2 million (up 1.3% YoY) and the FY2025 annual result came in at $68.0 million, up 4.72% from the prior year.
- Cash & Equivalents declined to $31.2 million in Q1 2026, from $68.0 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $96.1 million in Q4 2022 to a low of $21.5 million in Q4 2023.
- A 5-year average of $52.3 million and a median of $47.1 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 77.67% — and 2024, when it surged 202.43%.
- Tracing ARDX's Cash & Equivalents over 5 years: stood at $96.1 million in 2022, then tumbled by 77.67% to $21.5 million in 2023, then surged by 202.43% to $64.9 million in 2024, then grew by 4.72% to $68.0 million in 2025, then slumped by 54.1% to $31.2 million in 2026.
- The last three Cash & Equivalents figures came in at $31.2 million (Q1 2026), $68.0 million (Q4 2025), and $42.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 97.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.19 Mn |
| Mar 31, 2026 | 31.21 Mn |
| Dec 31, 2025 | 68.00 Mn |
| Sep 30, 2025 | 42.72 Mn |
| Jun 30, 2025 | 90.05 Mn |
| Mar 31, 2025 | 30.81 Mn |
| Dec 31, 2024 | 64.93 Mn |
| Sep 30, 2024 | 47.43 Mn |
| Jun 30, 2024 | 41.89 Mn |
| Mar 31, 2024 | 36.15 Mn |
| Dec 31, 2023 | 21.47 Mn |
| Sep 30, 2023 | 33.77 Mn |
| Jun 30, 2023 | 30.06 Mn |
| Mar 31, 2023 | 92.49 Mn |
| Dec 31, 2022 | 96.14 Mn |
| Sep 30, 2022 | 61.63 Mn |
| Jun 30, 2022 | 53.41 Mn |
| Mar 31, 2022 | 47.08 Mn |
| Dec 31, 2021 | 72.43 Mn |
| Sep 30, 2021 | 75.29 Mn |